Literature DB >> 3064031

Immunization against Plasmodium falciparum with recombinant polypeptides produced in Escherichia coli.

A A Holder1, R R Freeman, S C Nicholls.   

Abstract

Two proteins produced in recombinant Escherichia coli and containing amino acid sequences from the Plasmodium falciparum precursor to major merozoite surface antigens (PMMSA) have been partially purified. These proteins, together with a preparation of merozoites, have been used to immunize animals. The antibody response and the degree of protection were compared. Animals immunized with merozoites produced antibodies reacting with many P. falciparum proteins, whereas a response specific for PMMSA was detected in those receiving the recombinant material. Incomplete protection was conferred to both groups and there was no apparent correlation between antibody levels and protection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3064031     DOI: 10.1111/j.1365-3024.1988.tb00248.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  17 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum.

Authors:  G S Hui; A Hashimoto; S P Chang
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

3.  Development of natural immunity in Plasmodium falciparum malaria: study of antibody response by Western immunoblotting.

Authors:  J Thelu; I Sheick-Zakiuddin; C Boudin; F Peyron; S Picot; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 4.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus.

Authors:  G S Hui; C Hashiro; C Nikaido; S E Case; A Hashimoto; H Gibson; P J Barr; S P Chang
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 6.  Future potential of malaria vaccines.

Authors:  M Hommel
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 7.  Status of malaria vaccine research.

Authors:  G A Targett
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

8.  Allelic diversity and antibody recognition of Plasmodium falciparum merozoite surface protein 1 during hypoendemic malaria transmission in the Brazilian amazon region.

Authors:  L A Da Silveira; M L Dorta; E A Kimura; A M Katzin; F Kawamoto; K Tanabe; M U Ferreira
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

9.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum.

Authors:  H M Etlinger; P Caspers; H Matile; H J Schoenfeld; D Stueber; B Takacs
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.